# A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Source: https://onco.cc/trials/nct05473156/  
OnCo record `nct05473156` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AP203 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by AP Biosciences Inc., now recruiting.

## Summary

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies is a phase 1/2 interventional study registered as NCT05473156 by AP Biosciences Inc., with 168 participants planned, started 2023-07-24 and due to reach its primary completion in 2026-12. Interventions recorded: AP203.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05473156
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study of the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
- Sponsor: AP Biosciences Inc.
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT05473156: https://clinicaltrials.gov/study/NCT05473156

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- companies: [AP Biosciences](https://onco.cc/companies/ap-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05473156.json